Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Motion Sickness, Space, Motion Simulation, Parabolic Flight
About this trial
This is an interventional treatment trial for Motion Sickness, Space focused on measuring Astronauts, centrifugation, parabolic, operational
Eligibility Criteria
Inclusion Criteria: Subjects will involve astronauts assigned to spaceflight missions or test personnel assigned to operational activities that involve provocative motion (e.g., simulations or parabolic flights). No participants should have no neurologic, vestibular or autonomic disorders, or medical conditions that could be worsened by scopolamine (narrow-angle glaucoma or urinary retention) Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) negative test, confirmed by Food and Drug Administration (FDA) authorized COVID-19 test < 7 days prior to study drug administration or no COVID 19 symptoms up to 10 days prior to study drug administration. Note: There are no accepted forms of terrestrial motion analogs that adequately predict susceptibility to space motion sickness so none will be used in this field test. Exclusion Criteria: Subjects will be excluded if they are taking other drugs that are capable of causing CNS effects such as antihistamines, tricyclic antidepressants, and muscle relaxants or have hypersensitivity to scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system. Pregnant women are excluded from participation. Women of child-bearing potential will be offered a pregnancy screening test and excluded with a positive test.
Sites / Locations
- NASA Johnson Space Center Neuroscience LaboratoryRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
DPI-386 Nasal Gel
Control
DPI-386 Nasal Gel, 0.4 mg
Another form of preventative or treatment medication for motion sickness (e.g., promethazine or meclizine)